Non-recognized liver impairment in critically ill patients is frequent and hazardous

JU Jensen¹, L Peters¹, TS Itenov², ME Johansen¹, MH Beelke¹, AØ Lauritsen², T Mohr², K Thormar³, J Løken⁴, P See-Jensen⁵, PH Christensen⁶, MH Andersen⁷, J Grarup¹, JD Lundgren¹

¹CHIP, Centre for Health & Infectious Diseases Research, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen; ²Department of Anaesthesia and Intensive Care, North Zealand Hospital; ³Department of Anaesthesia and Intensive Care, Hvidovre Hospital; ⁴Department of Anaesthesia and Intensive Care, Herlev Hospital;
⁵Dako diagnostics; ⁶Department of Anaesthesia and Intensive Care, Aarhus University Hospital; ⁷Diagnostic Centre, Rigshospitalet, Copenhagen. All Denmark

BACKGROUND

The incidence and clinical importance of acute liver impairment in critically ill patients is debated. Hyaluronic acid (HA) is released from connective tissue, hepatically eliminated and has been shown to reflect liver function and prognosis in other populations. The aim of the current study was:

i) to determine how frequent intensive care patients suffer from clinically relevant liver impairment

ii) to determine whether this potential liver impairment has impact on 28-day survival.

METHODS

A 1,200 intensive care patient cohort from a randomized trial (> 80% infected). Patients were excluded if stored serum specimens were too sparse for HA analysis, and if the liver biomarkers bilirubin, INR and Model for End-stage Liver Disease (MELD) were not available at baseline.

All patients with chronic liver disease were excluded. In the final cohort of 839 patients (figure 1) all had HA measured in an immunoturbidimetric assay (HA in healthy controls is ~40 ng/mL).

RESULTS

Biomarker levels at baseline were (median [IQR]). HA (ng/mL): 153.6 [67.9 – 459.5], INR: 1.3 [1.1 – 1.6], bilirubin (mg/dL): 0.53 [0.29 – 0.88], MELD: 13.9 [9.9 – 20.4]. Significant correlations were present between all liver markers (rho 0.15 – 0.56). The mortality risk corresponded directly to the HA quartile they belonged to. The 28-day mortality was ~55% for patients in the 4th quartile vs. ~22% in 1st quartile, logrank, p=0.0001 (figure 2). In a multivariable Cox regression model adjusted for known and suspected predictors of mortality, HA quartile III (HR 1.5 [95% CI: 1.0 – 2.5]) and IV (HR 1.9 [95% CI: 1.3 – 2.9]) were found to be strong independent predictors of mortality in intensive care patients (ref Q1). Substantially higher risk was also found in the upper quartile for bilirubin (HR 1.6 [95% CI: 1.1 – 2.3]).

CONCLUSION

Liver impairment, measured by three liver biomarkers and MELD, was frequent in these critically ill patients and was highly predictive for mortality. It is biologically plausible that patients who suffer from liver impairment in critical illness will also be less likely to be able to react adequately to a severe infection and therefore at a higher risk of dying.

The mechanisms causing this liver impairment should be explored to detect targets for interventions to improve outcome.

Acknowledgements: Corgenix Medical Corporation, Broomfield, CO, USA kindly funded the Hyaluronic Acid kits

Download poster at: www.chip.dk